DENVER--(BUSINESS WIRE)--Feb. 6, 2006--Lifeline Therapeutics, Inc. (“Lifeline” or the “Company”) (OTCBB: LFLT), maker of Protandim(R), today announced that it has filed Form SB-2 Amendment 1 with the Securities and Exchange Commission. The document is a response to inquiries made by the SEC following the filing of the Company’s registration statement filed on June 30, 2005.
